Search results for " hepatocellular"

showing 10 items of 592 documents

Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Before Liver Transplantation: A Prospective Study with Histopathologic Comparison

2006

OBJECTIVE. The aims of this study were to determine the feasibility and efficacy of percutaneous radiofrequency ablation in patients with hepatocellular carcinoma waiting for liver transplantation and to compare the radiologic and pathologic findings. SUBJECTS AND METHODS. Twenty-six patients with 35 hepatocellular carcinomas were addressed for transplantation. Complications of the procedures were recorded. Primary and secondary technique effectiveness and causes of exclusion from the waiting list were assessed. After transplantation, tumor recurrence was evaluated for at least 1 year in all patients. Radiologic-pathologic comparison of the explant was performed. RESULTS. Percutaneous radio…

Malemedicine.medical_specialtyCarcinoma HepatocellularPercutaneousRadiofrequency ablationmedicine.medical_treatmentLiver transplantationlaw.inventionlawPreoperative CaremedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyablation cancer hepatocellular carcinoma liver transplantation radiofrequencybusiness.industryLiver NeoplasmsCancerGeneral MedicineMiddle Agedmedicine.diseaseAblationLiver TransplantationSurgeryRadiographyTransplantationHepatocellular carcinomaCatheter AblationFeasibility StudiesFemaleRadiologybusinessFollow-Up StudiesAmerican Journal of Roentgenology
researchProduct

Midterm follow-up after DC-BEAD™-TACE of Hepatocellular Carcinoma (HCC)

2012

Abstract Aim To determine local response, its predictors and survival and complication rates after DC-Bead™-TACE in patients with hepatocellular carcinoma (HCC). Materials and methods DC-Beads™ are non-resorbable, polyvinyl-alcoholic hydrophilic microspheres. They release high amounts of chemotherapeutics directly into the tumour. Delivery is sustained over time, tumour feeders are embolised. We used beads from 100–300 to 500–700 μm loaded with Doxorubicin (max. 150 mg/4 ml). Fifty patients (mean age: 68.5 ± 8.8 years) with HCC were analysed. DC-Bead™-TACE was performed once or repeated in two-month intervals. Imaging scans (CT or MRI) were done one-month following each procedure. To evalua…

Malemedicine.medical_specialtyCarcinoma HepatocellularPleural effusionAntineoplastic AgentsComorbidityGastroenterologyRisk FactorsGermanyInternal medicinePrevalencemedicineCarcinomaHumansRadiology Nuclear Medicine and imagingChemoembolization TherapeuticSurvival rateSurvival analysisAgedUltrasonographybusiness.industryLiver NeoplasmsGeneral Medicinemedicine.diseaseSurvival AnalysisSurgerySurvival RateTreatment OutcomeDoxorubicinDelayed-Action PreparationsHepatocellular carcinomaFemaleLiver functionbusinessProgressive diseaseFollow-Up StudiesLiver abscessEuropean Journal of Radiology
researchProduct

Incidence of new foci of hepatocellular carcinoma after radiofrequency ablation: role of multidetector CT

2012

Purpose. The authors sought to assess the incidence of new foci of hepatocellular carcinoma (HCC) using multidetector computed tomography (MDCT) in patients treated with radiofrequency ablation (RFA). Materials and methods. Two readers retrospectively reviewed by consensus the follow-up MDCT studies of 125 patients (88 men and 37 women; mean age 68 years) with 141 HCCs (size 1–5.2 cm; mean 2.2 cm) treated with RFA. MDCT follow-up was performed at 1 and 3 months and every 6–12 months thereafter. Reviewers assessed: (1) the presence of new HCC foci in the same liver segment or in a different segment; (2) complete or incomplete tumor ablation; (3) tumour progression. Results. A total of 113 ne…

Malemedicine.medical_specialtyCarcinoma HepatocellularRadiofrequency ablationMultidetector ctSettore MED/01 - Statistica Medicalaw.inventionLiver neoplasmslawMultidetector Computed TomographymedicineHumansRadiology Nuclear Medicine and imagingAgedRetrospective StudiesNeuroradiologyChi-Square Distributionmedicine.diagnostic_testbusiness.industryIncidenceIncidence (epidemiology)Radiofrequency ablation (RFA)UltrasoundInterventional radiologyGeneral MedicineMiddle AgedHCCSmedicine.diseasedigestive system diseasesTreatment OutcomeLiverHepatocellular carcinomaCatheter AblationDisease ProgressionRadiofrequency ablation (RFA); Liver; CT; Liver neoplasmsFemaleRadiologyNeoplasm Recurrence LocalSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessFollow-Up StudiesCTLa radiologia medica
researchProduct

The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center

2019

Aims. To analyze the main etiological factors and some clinical features of patients with hepatocellular carcinoma (HCC) at diagnosis and to compare them with those we described ten years ago. Materials and Methods. We compared two groups of patients with HCC, Group 1 consisting of 132 patients (82 M, 50 F) diagnosed in the 2003–2008 period and Group 2 including 119 patients (82 M, 37 F) diagnosed in the 2013–2018 period. For all patients, age, sex, viral markers, alcohol consumption, serum alpha-fetoprotein (AFP) levels, and the main liver function parameters were recorded. The diagnosis of HCC was based on AASLD, EASL guidelines. The staging was classified according to the “Barcelona Clin…

Malemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaArticle SubjectSingle CenterGastroenterologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesEpidemiology Hepatocellular carcinoma HCV HBV NASH0302 clinical medicineRisk FactorsInternal medicineEpidemiologyHumansMedicineStaging systemAgedNeoplasm StagingGeneral Immunology and Microbiologybusiness.industryLiver NeoplasmsRGeneral MedicineHepatitis Bmedicine.diseaseHepatitis Cdigestive system diseases030220 oncology & carcinogenesisHepatocellular carcinomaEtiologyMedicineViral MarkersFemale030211 gastroenterology & hepatologyalpha-FetoproteinsLiver functionbusinessLiver cancerResearch ArticleBioMed Research International
researchProduct

Liver Transplantation for Hepatocellular Carcinoma After Yttrium Therapy: A Case Report

2008

Yttrium-90 microspheres constitute one of the most recent treatment options for hepatocellular carcinoma (HCC) in the setting of cirrhosis. As such, their spectrum of indication is not yet fully established. Herein, we have reported the case of a patient with HCC beyond the listing criteria for liver transplantation (OLT) who was treated preoperatively with selective transarterial chemoembolization and yttrium-90 microspheres. He was subsequently transplanted with a liver from an 81-year-old donor allocated through Eurotransplant as a "rescue offer." The posttransplant course was uneventful. Pathologic examination revealed a multifocal, well-differentiated pT2 tumor with no vascular invasio…

Malemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentLiver transplantationMicrospheremedicineHumansYttrium RadioisotopesChemoembolization TherapeuticAged 80 and overTransplantationbusiness.industryLiver NeoplasmsCancerTreatment optionsMiddle Agedmedicine.diseaseCombined Modality TherapyLiver TransplantationTumor recurrenceSurgeryTreatment Outcomesurgical procedures operativeHepatocellular carcinomaSurgerybusinessLiver cancerTransplantation Proceedings
researchProduct

The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transpl…

2020

BACKGROUND There is a lack of data on the use of direct-acting antivirals (DAA) on the risk of death and tumoral recurrence in patients with hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) listed for liver transplantation (LT). We aimed to assess the impact of antiviral treatment on mortality and HCC recurrence patients with HCC-HCV. METHODS This was a retrospective multicenter study of patients with HCC-HCV listed for LT from 2005 to 2015. Patients were divided according to the antiviral treatment received after HCC diagnosis: DAA, interferon (IFN), or no antiviral. Intention-to-treat overall survival and HCC recurrence incidence were compared by the Kaplan-Meier method. Multiva…

Malemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsWaiting Listsmedicine.medical_treatment030230 surgeryLiver transplantationGastroenterologyAntiviral AgentsRisk Assessment03 medical and health sciences0302 clinical medicineInterquartile rangeRisk FactorsInternal medicineCarcinomamedicineHumansRisk factorRetrospective StudiesTransplantationbusiness.industryIncidence (epidemiology)Hazard ratioLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesLiver TransplantationTreatment OutcomeHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleNeoplasm Recurrence LocalbusinessTransplantation
researchProduct

Androgen metabolism and biotransformation in nontumoral and malignant human liver tissues and cells

2009

There is indirect multiple evidence that hints at a potential role of sex steroids in development and progression of human hepatocellular carcinoma (HCC). In the present study, we have investigated androgen metabolism in a panel of human liver cancer cell lines (HA22T, Huh7, HepG2) and in normal, cirrhotic and malignant human liver tissues aiming to dissect the potential impact of individual enzyme activities and their products in normal and diseased human liver, both in vivo and in vitro. Using our intact cell analysis we were able to assess rates and pathways of androgen metabolism in living conditions. Overall, incubation of cultured cells or tissue minces with either testosterone (T) or…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.drug_classEndocrinology Diabetes and MetabolismClinical BiochemistryBiochemistryEndocrinologyAromataseInternal medicineCell Line TumormedicineHumansTestosteroneAromataseMetabolism estrogenandrogen normal liver liver cirrhosisMolecular BiologyTestosteroneAromatase inhibitorbiologyAromatase InhibitorsLiver cellLiver NeoplasmsAndrostenedioneCell BiologyAndrogenmedicine.anatomical_structureEndocrinologyLiverSelective estrogen receptor modulatorEstrogenHepatocytebiology.proteinAndrogensMolecular MedicineFemale
researchProduct

Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report.

2009

Abstract Background Transmission of donor-derived cancer by organ transplantation is rare, but the risk has been increasing due to the aging donor pool. Undifferentiated neuroendocrine small-cell carcinoma is an agressive tumor with the tendency to spread. Herein we have demonstrated different approaches to treat organ recipients with transmitted tumors. Methods and Results Grafts were retrieved from a decreased donor without any history of previous diseases. Autopsy was not performed after donation. The recipient of the liver graft presented with suspected nodules on routine abdominal ultrasound. After computed tomography (CT) scan, biopsy confirmed the diagnosis of a small-cell carcinoma.…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAutopsyAntineoplastic AgentsSmall-cell carcinomaNephrectomyOrgan transplantationCarboplatinalpha 1-Antitrypsin DeficiencyBiopsymedicineCarcinomaHumansCarcinoma Small CellNeoplasm MetastasisEtoposideTransplantationChemotherapymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseaseDNA FingerprintingEmbolization TherapeuticKidney TransplantationTissue DonorsSurgeryLiver TransplantationTransplantationHeart TransplantationSurgerybusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma.

2006

Criteria to select patients with hepatocellular carcinoma (HCC) for liver transplantation (LT) are based on tumor size and number of nodules rather than on tumor biology. The present study was undertaken to assess the role of transarterial chemoembolization (TACE) in selecting patients with tumors suitable for LT. Ninety-six consecutive patients with HCC were treated by repeatedly performed TACE, 62 of them exceeding the Milan criteria. Patients meeting the Milan criteria were immediately listed, and patients beyond the listing criteria were listed upon downstaging of the tumor following successful TACE. Fifty patients were finally transplanted. Of these 50 patients, 34 exceeded the Milan c…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentKaplan-Meier EstimateLiver transplantationMilan criteriaGastroenterologyRecurrenceInternal medicineCarcinomaMedicineHumansChemoembolization TherapeuticSurvival rateRetrospective StudiesTransplantationHepatologybusiness.industryPatient SelectionLiver NeoplasmsRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationTransplantationSurvival RateTreatment OutcomeHepatocellular carcinomaRelative riskDisease ProgressionSurgeryFemalebusinessLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
researchProduct

Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials

1997

Summary Background Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death. Many treatments have been proposed but considerable uncertainty still remains about their effectiveness. In this review we evaluated the quality, clinical coherence, consistency and results of Randomized Controlled Trials (RCT) of non-surgical treatments for HCC. Methods Thirty-seven RCTs examining the effect of different treatments were retrieved using MEDLINE (November 1978 to December 1995) and a review of reference lists. Selected aspects of the quality of design, conduct and reporting were examined. The odds ratio for the probability of surviving up to one year was calculated according to the …

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentlaw.inventionRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAdjuvant therapyHumansEmbolizationRandomized Controlled Trials as Topicbusiness.industryArterial EmbolizationLiver NeoplasmsHematologyOdds ratioEmbolization TherapeuticChemotherapy regimenSurgeryClinical trialClinical Trials Phase III as TopicOncologyMeta-analysisImmunotherapybusinessAnnals of Oncology
researchProduct